Ticker: HROW

Harrow Health (NASDAQ: HROW) reported a 46% revenue increase to $48.9M in Q2 2024, driven by its Anterior Segment business. CEO Mark Baum highlighted strong growth in branded products and plans for expanded sales efforts. Positive outlook on 2024 growth amidst cautious projections.